[Establishment and biological characterization of 5-fluorouracil-resistant human colon cancer HT-29/5-FU cell line].
OBJECTIVE
To establish 5-fluorouracil (5-FU)-resistant human colon cancer HT-29 cell line (HT-29/5-FU) in vitro and observe its biological properties.


METHODS
The HT-29/5-FU cell line was established by continuously exposing the HT-29 cells to ascending doses of 5-FU. The morphology and colony formation rate were detected. The growth curve and the chemosensitivity of HT-29/5-FU cell line were determined by MTT assay. Western blotting was used to analyze the expressions of thymidylate synthase (TS) and dihydropyrimidine dehydrogenase (DPD). Cell cycle and apoptosis were measured by flow cytometry.


RESULTS
The resistance of HT-29/5-FU cells to 5-FU was 3.59-fold greater than that of HT-29 cells. The morphology of HT-29/5-FU cells differed from that of HT-29 cells. Compared with HT-29 cells, HT-29/5-FU cells showed remarkable reduction of cell proliferation and colony formation, higher expressions of TS and DPD, higher percentage of cells in the S phase, and stronger ability of resistance to apoptosis induced by 5-FU.


CONCLUSIONS
The biological characters of HT-29/5-FU cell line may play an important role in 5-FU-resistant mechanisms, which may also contribute to elucidate the potential mechanisms of tumor drug resistance as well as resistance reversal.
Department of Oncology, First Affiliated Hospital, Nanchang University, Nanchang 330006, China.
Tingting
T
Qiu
Department of Oncology, First Affiliated Hospital, Nanchang University, Nanchang 330006, China.
Xiaojun
X
Xiang
Department of Oncology, First Affiliated Hospital, Nanchang University, Nanchang 330006, China.
Wan
W
Lei
Institute of Urology, Nanchang University, Nanchang 330006, China.
Chao
C
Hao
Department of Oncology, First Affiliated Hospital, Nanchang University, Nanchang 330006, China.
Ling
L
Zhang
Department of Oncology, First Affiliated Hospital, Nanchang University, Nanchang 330006, China.
Miao
M
Feng
Department of Oncology, First Affiliated Hospital, Nanchang University, Nanchang 330006, China.
Feng
F
Yu
Department of Oncology, First Affiliated Hospital, Nanchang University, Nanchang 330006, China.
Junhe
J
Li
Department of Oncology, First Affiliated Hospital, Nanchang University, Nanchang 330006, China.
Jianping
J
Xiong
D017209:Apoptosis / Q000187:drug effects; D002453:Cell Cycle / Q000187:drug effects; D049109:Cell Proliferation / Q000187:drug effects; D003110:Colonic Neoplasms / Q000188:drug therapy* / Q000235:genetics / Q000378:metabolism / Q000503:physiopathology; D042943:Dihydrouracil Dehydrogenase (NADP) / Q000235:genetics / Q000378:metabolism; D019008:Drug Resistance, Neoplasm; D005472:Fluorouracil / Q000494:pharmacology*; D019073:HT29 Cells / Q000166:cytology / Q000187:drug effects* / Q000201:enzymology; D006801:Humans; D013940:Thymidylate Synthase / Q000235:genetics / Q000378:metabolism
D042943:Dihydrouracil Dehydrogenase (NADP); D013940:Thymidylate Synthase; D005472:Fluorouracil